Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KCNJ6 | P48051 | 14/20 | 0.46 |
| ▸ | KCNJ3 | P48549 | 14/20 | 0.46 |
| ▸ | KCNJ5 | P48544 | 9/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21847656 | 0.82 | KCNJ6 (0.34) | KCNJ6KCNJ3KCNJ5KDM4EALDH1A1 | |
| SCHEMBL15428754 | 0.80 | KCNJ6 (0.47) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL1695151 | 0.79 | KDM4E (0.47) | MAPTKCNJ6KCNJ3KCNJ5KDM4E | |
| SCHEMBL1695184 | 0.79 | ALDH1A1 (0.44) | KCNJ6KCNJ3KCNJ5KDM4EALDH1A1 | |
| SCHEMBL14785716 | 0.78 | POLB (0.41) | MAPTKDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL1695102 | 0.77 | KDM4E (0.50) | MAPTKCNJ6KCNJ3KCNJ5KDM4E | |
| SCHEMBL11701379 | 0.77 | MAPT (0.45) | MAPTKCNJ6KCNJ3KCNJ5KDM4E | |
| SCHEMBL1695005 | 0.74 | GAA (0.54) | KDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL12179262 | 0.73 | MAPT (0.47) | MAPTKCNJ6KCNJ3KCNJ5KDM4E | |
| SCHEMBL12829947 | 0.72 | MAPT (0.50) | MAPTKCNJ6KCNJ3KCNJ5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1820504-A1 | IMINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | MAPT 4160/4885KCNJ6 428/4885KCNJ3 310/4885 |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | MAPT 4201/4885KCNJ6 1306/4885KCNJ3 1553/4885 |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | MAPT 4201/4885KCNJ6 1306/4885KCNJ3 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.